These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37525557)

  • 41. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
    Hoffknecht P; Tufman A; Wehler T; Pelzer T; Wiewrodt R; Schütz M; Serke M; Stöhlmacher-Williams J; Märten A; Maria Huber R; Dickgreber NJ;
    J Thorac Oncol; 2015 Jan; 10(1):156-63. PubMed ID: 25247337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
    Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer.
    Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Thorac Cancer; 2023 Feb; 14(4):348-356. PubMed ID: 36525509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
    Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
    Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.
    Tamura K; Nukiwa T; Gemma A; Yamamoto N; Mizushima M; Ochai K; Ikeda R; Azuma H; Nakanishi Y
    Int J Clin Oncol; 2019 Aug; 24(8):917-926. PubMed ID: 30953238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
    Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
    BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
    Ninomiya T; Ishikawa N; Inoue K; Kubo T; Yasugi M; Shibayama T; Maeda T; Fujitaka K; Kodani M; Yokoyama T; Kuyama S; Ochi N; Ueda Y; Miyoshi S; Kozuki T; Amano Y; Kubota T; Sugimoto K; Bessho A; Ishii T; Watanabe K; Oze I; Hotta K; Kiura K
    Clin Lung Cancer; 2019 Mar; 20(2):134-138. PubMed ID: 30514667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-Line Afatinib plus Cetuximab for
    Cortot AB; Madroszyk A; Giroux-Leprieur E; Molinier O; Quoix E; Bérard H; Otto J; Rault I; Moro-Sibilot D; Raimbourg J; Amour E; Morin F; Hureaux J; Moreau L; Debieuvre D; Morel H; Renault A; Pichon E; Huret B; Charpentier S; Denis MG; Cadranel J
    Clin Cancer Res; 2021 Aug; 27(15):4168-4176. PubMed ID: 34031056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
    Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Afatinib for the treatment of
    Harvey RD; Adams VR; Beardslee T; Medina P
    J Oncol Pharm Pract; 2020 Sep; 26(6):1461-1474. PubMed ID: 32567494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
    Brueckl WM; Reck M; Schäfer H; Neben K; Griesinger F; Rawluk J; Krüger S; Kokowski K; Ficker JH; Möller M; Schueler A; Laack E
    J Geriatr Oncol; 2023 Jan; 14(1):101394. PubMed ID: 36323612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.